1.Ralston, SJ, Lorenzo, MJ, ADORE Study Group. ADORE – Attention-Deficit Hyperactivity Disorder Observational Research in Europe. Eur Child Adolesc Psychiatr 2004; 13: 136–142.
2.Li, WY, Strang, SE, Brown, DR, et al. Atomoxetine changes rat's HR response to stress from tachycardia to bradycardia via alterations in autonomic function. Auton Neurosci 2010; 154: 48–53.
3.Wernicke, JF, Faries, D, Girod, D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Safe 2003; 26: 729–740.
4.Barr, CS, Naas, A, Freeman, M, Lang, CC, Struthers, AD. QT Dispersion and sudden unexpected death in chronic heart failure. The Lancet 1994; 343: 327–329.
5.Merx, W, Yoon, MS, Han, J. The role of local disparity in conduction and recovery time on ventricular vulnerability to fibrillation. Am Heart J 1977; 94: 603–610.
6.Etheridge, SP, Shaddy, RE. QT dispersion after beta-blocker therapy in children with heart failure. Am J Cardiol 2003; 91: 1–5.
7.Zabel, M, Klingenheben, T, Franz, M, Hohnloser, S. Assessment of QT dispersion for prediction of mortality or arrhythmic events after myocardial infarction. Circulation 1998; 97: 2543–2550.
8.Tutar, HE, Ocal, B, Imamoglu, A, Atalay, S. Dispersion of QT and QTc interval in healthy children, and effects of sinus arrhythmia on QT dispersion. Heart 1998; 80: 77–79.
9.Kaufman, J, Birmaher, B, Brent, D. Schedule for affective disorders and schizophrenia for school age children – present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatr 1997; 36: 980–988.
10.Bazett, HC. An analysis of the time relations of electrocardiograms. Heart 1920; 7: 353.
11.Kimball, TR, Michelfelder, EC. Echocardiography. In: Allen, HD, Driscoll, DJ, Shaddy, RE, Feltes, TF (eds). Moss and Adams’ heart disease in infants, children, and adolescents: including the fetus and young adult, 7th edn. Lippincott Williams & Wilkins, Philadelphia, PA, 2008, pp 95–163.
12.Walsh, EP, Saul, P. Cardiac arrhythmias. In: Fyler, DC (ed.). Nadas’ pediatric cardiology. Hanley and Belfus Inc., Philadelphia, PA, 1992, pp 377–434.
13.Bednar, MM, Harrigan, EP, Ruskin, JN. Torsade de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 2002; 89: 1316–1319.
14.Spencer, T, Biederman, J, Heiligenstein, J, et al. An open label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11: 251–265.
15.Kratochvil, CJ, Wilens, TE, Greenhill, LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatr 2006; 45: 919–927.
16.Allen, AJ, Kurlan, RM, Gilbert, DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005; 65: 1941–1949.
17.Kautzner, J, Malik, M. QT interval dispersion and its clinical utility. Pacing Clin Electrophysiol 1997; 20: 2625–2640.
18.Statters, DJ, Malik, M, Ward, DE, Camm, AJ. QT dispersion: problems of methodology and clinical significance. J Cardiovasc Electrophysiol 1994; 5: 672–685.
19.Davey, PP, Bateman, J, Mulligan, IP, Forfar, C, Barlow, C, Hart, G. QT interval dispersion in chronic heart failure and left ventricular hypertrophy: relation to autonomic nervous system and Holter tape abnormalities. Br Heart J 1994; 71: 268–273.
20.Shah, CP, Thakur, RK, Reisdorff, EJ, Lane, E, Aufderheide, TP, Hayes, OW. QT dispersion may be a useful adjunct for detection of myocardial infarction in the chest pain center. Am Heart J 1998; 136: 496–498.
21.Day, CP, McComb, JM, Campbell, RWF. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990; 63: 342–344.
22.Grimm, W, Steder, U, Menz, V, Hoffmann, J, Maisch, B. QT dispersion and arrhythmic events in idiopathic dilated cardiomyopathy. Am J Cardiol 1996; 78: 458–461.
23.Michelson, D, Read, HA, Ruff, DD, Witcher, J, Zhang, S, McCracken, J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatr 2007; 46: 242–251.
24.Spencer, T, Heiligenstein, JH, Biederman, J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatr 2002; 63: 1140–1147.
25.Donnelly, C, Bangs, M, Trzepacz, P, et al. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatr 2009; 48: 176–185.